Leukemia mutation patterns linked to age and survival
An observational study of 1,360 adults with a genetically defined blood cancer mapped age-related mutation patterns and their links to prognosis.
Our read
Mechanisms- Studied:
- Cohort study of 688 adults with NPM1-mutated acute myeloid leukemia (Multicenter)
- What changed:
- Overall survival was lower with older age and SRSF2 mutations among patients receiving intensive therapy
- The catch:
- Prognostic analyses excluded patients receiving other care, potentially biasing mutation–survival associations
- In the record:
- The 6th paper on SRSF2 with results in people; 46 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
Researchers retrospectively studied 1,360 adults with NPM1-mutated acute myeloid leukemia, a blood cancer defined by changes in the NPM1 gene. This multicenter observational study found additional mutations in 97% of patients, with a median of three mutations. Different mutation groups were more common in younger and older adults, and older patients carried more mutations overall.
The researchers also examined prognosis among 688 patients who received intensive therapy as their initial treatment. After accounting for other factors, older age and changes in SRSF2, a gene involved in processing RNA, were independently linked to worse overall survival and survival without relapse. Other mutations had different associations with survival and relapse.
Why it matters
Risk assessment for this blood cancer currently centers on one additional mutation. The authors concluded that considering broader mutation patterns could refine assessment across age groups.
Caveats
The retrospective observational design identifies associations, not cause and effect. The prognostic findings described here came from patients receiving intensive therapy and may not apply to patients receiving other care.
- Epigenetic regulation of gene expression
- MAPK/ERK signaling
- Acute myeloid leukemia
- Relapse
- Cytopenic disease
- Humans
The paper
Instituto de Investigación Sanitaria La Fe; Hospital Universitari i Politècnic La Fe
Haematologica, Jul 16, 2026, Open access




Comments
Be the first to comment.